Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Original Article
T. Facon, M.-A. Dimopoulos, X.P. Leleu, M. Beksac, L. Pour, R. Hájek, Z. Liu, J. Minarik, P. Moreau, J. Romejko-Jarosinska, I. Spicka, V.I. Vorobyev, B. Besemer, T. Ishida, W. Janowski, S. Kalayoglu-Besisik, G. Parmar, P. Robak, E. Zamagni, H. Goldschmidt, T.G. Martin, S. Manier, M. Mohty, C. Oprea, M.-F. Brégeault, S. Macé, C. Berthou, D. Bregman, Z. Klippel, and R.Z. Orlowski
N Engl J Med 2024;391:1597-1609
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Please sign in or create an account to take the course.